Loading stock…

Bachem Holding AG (BANB) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Bachem Holding AG

BANBMarket cap $7.22BPrice $96.4

Country🇨🇭Switzerland

SectorHealthcare

IndustryLife Sciences

Manufactures peptides and oligonucleotides for drug makers worldwide, the tiny molecular building blocks behind GLP-1 weight-loss drugs and cancer therapies. Bachem supplies ingredients to nearly every major pharma company, making it a hidden powerhouse behind blockbuster medicines you've definitely heard of.

In Bastion Portfolios?

52W Return+41%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+15%8

Revenue Forecast

Rev CAGR (1y)+29%9

Rev CAGR (3y)+25%9

Rev CAGR (5y)+20%9

Earnings Forecast

EPS Growth Y+1+16%8

EPS Growth Y+2+26%8

EPS Growth Y+3+16%8

Quality

Margins

EBIT Margin22%8

Net Income Margin21%8

Free Cash Flow Margin-7%2

Debt

Net Debt/EBITDA0.76

Efficiency

ROE11%5

ROA7%7

Earnings Stability77

GEAR+AVERAGE63

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)292

P/E Ratio (Forward 3y)232

P/BV4.34

EV Multiples

EV/EBITDA Fwd212

EV/EBIT Fwd292

Yield

Free Cash Flow Yield-0.8%2

Dividend Yield0.6%2

Momentum

Short term

1 month return+4%9

3 month return+6%8

YTD return+36%9

Mid term

Price vs 52wHigh95%9

1 year return+35%8

Long term

3 year return+15%4

5 year return-43%2

Risk Shield

Price Risk

Beta1.23

Volatility40%5

Free Cash Flow

Free Cash Flow Margin-7%2

Free Cash Flow Yield-0.8%2

Quality

ROCE9%5

Earnings Stability77

Net Debt/EBITDA0.76

02Growth

Is it actually growing, and how fast?

BANBBachem Holding

Revenue FY25$877M

GROWTH RATING↗

VERY STRONG91 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y+29%9

Revenue, next 3Y, CAGR+25%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+16%8

EPS growth, FY27E+26%8

EPS growth, FY28E+16%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 91% of companies worldwide.

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 25%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 15%/yr over the last 3 years and is set to grow 25%/yr from here.

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Earnings are set to grow slower than sales (EPS about 16%/yr vs revenue 25%/yr), so margins are under pressure.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up. The one thing to watch: earnings are set to grow slower than sales.

03Price Momentum

Is the market behind it right now?

BANBBachem Holding

Total return Current509%

Price return Current443%

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+6%8

YTD return+36%9

MID & LONG-TERM▾SCORE

% of 52-week high95%9

1-year return+35%8

3-year return+15%4

5-year return-43%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 35% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+6%) and so far this year (+36%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+15% over three years and -43% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Bachem Holding AG. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

BANBBachem Holding

Revenue FY25$877M

GROWTH RATING↗

VERY STRONG91 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y+29%9

Revenue, next 3Y, CAGR+25%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+16%8

EPS growth, FY27E+26%8

EPS growth, FY28E+16%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 91% of companies worldwide.

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 25%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 15%/yr over the last 3 years and is set to grow 25%/yr from here.

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Earnings are set to grow slower than sales (EPS about 16%/yr vs revenue 25%/yr), so margins are under pressure.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up. The one thing to watch: earnings are set to grow slower than sales.

03Price Momentum

Is the market behind it right now?

BANBBachem Holding

Total return Current509%

Price return Current443%

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+6%8

YTD return+36%9

MID & LONG-TERM▾SCORE

% of 52-week high95%9

1-year return+35%8

3-year return+15%4

5-year return-43%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 35% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+6%) and so far this year (+36%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+15% over three years and -43% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Bachem Holding AG. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community